1e
19
1
49
2
2
18
1b
1d
18
31
59
1d
2 29
1d
25
Jennifer R Eads, MD
88
59
Professor of Clinical Medicine (Hematology-Oncology)
28
a4
3
5f
Principal Investigator, Eastern Cooperative Oncology Group, University of Pennsylvania Abramson Cancer Center
95
Director, National Clinical Trials Network, University of Pennsylvania, Abramson Cancer Center
11
Department: Medicine
4
1
b
1d
46
Contact information
54
4
3
3
3
2
29
54
Perelman Center for Advanced Medicine
3c 10th Floor South Pavilion
Philadelphia, PA 19104
26
3c 10th Floor South Pavilion
Philadelphia, PA 19104
35
a9
12
Links
7e Main website for the North American Neuroendocrine Tumor Society
95 Penn Neuroendocrine Tumor Program
65 Neuroendocrine Tumor Research Foundation
c
4
b
1f
7e Main website for the North American Neuroendocrine Tumor Society
95 Penn Neuroendocrine Tumor Program
65 Neuroendocrine Tumor Research Foundation
c
13
Education:
21 7 BS 16 (Genetics ) c
39 University of California, Davis , 1999.
21 7 MD c
3d Tufts University School of Medicine , 2005.
c
3
3
3
3
8d
Permanent link21 7 BS 16 (Genetics ) c
39 University of California, Davis , 1999.
21 7 MD c
3d Tufts University School of Medicine , 2005.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
40 neuroendocrine tumors and esophagogastric cancer71
Description of Research Expertise
40 neuroendocrine tumors and esophagogastric cancere 29
23
1e3 Capdevila J, Artamonova E, De Jesus Acosta A, Niccoli P, Toth M, Ramirez R, Hendifar A, Cingarlini S, Trikalinos NA, Quante M, Garcia-Carbonero R, Goder E, del Rivero J, Eads JR, Odeleye-Ajakaye A, Gozman A, Naik GS, Spada F: Belzutifan for advanced pancreatic neuroendocrine tumors (panNETs): results from cohort A2 of the phase 2 LITESPARK-015 study. European Society of Medical Oncology Annual Meeting 2025.
159 Eads JR, Morelli MP, Olson D, Litten JB, Astrow SH, Pelster M: A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers. J Clin Oncol 2025.
23e Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O’Hara MH, Eads JR, King D, Shah MM, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA: Incorporating circulating tumor DNA testing into clinical trials: a position paper by the National Cancer Institute GI Oncology circulating tumor DNA working group. JCO Precision Oncology 2025.
21e Eads JR, Graham N, Gibson MK, Rajdev L, Chakravarthy AB, Khullar OV, Lin SH, Wistuba II, Agarwal R, Blazar M, Mehta DR, Al Baghdadi T, Jin N, Massa RC, Hamilton SR, Staley CA, Wong TZ, O’Dwyer PJ: A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients with locoregional esophageal and gastroesophageal junction adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). J Clin Oncol 2024.
132 Lee H, Kipnis S, O’Brien S, Eads JR, Katona BW, Pryma DA: Real-world 177Lu-DOTATATE peptide receptor radionucleotide therapy: treatment outcomes with dosing variations an in non-midgut neuroendocrine tumors. ASCO GI Symposium 2024.
d3 Eads JR: Episode 26: Neuroendocrine Neoplasms: Focus on Immunotherapy. Los Angeles Carcinoid Neuroendocrine Tumor Foundation Podcast 2024.
1c2 Li Y, Wu S, Zhao Y, Dinh T, Jiang D, Selfridge JE, Myers G, Wang Y, Zhao X, Tomchuck S, Dubyak G, Lee RT, Estfan B, Shapiro M, Kamath S, Mohamed A, Huang SC, Huang AY, Conlon R, Krishnamurthi S, Eads J, Willis JE, Khorana AA, Bajor D, Wang Z: Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer. J Clin Invest 2024.
c7 Chapin WJ, Massa R, Eads JR: Defining the role of neoadjuvant therapy for gastroesophageal cancers. Advances in Oncology 2024.
17e Soulen MC, Teitelbaum UR, Mick R, Eads J, Mondschein JL, Dagli M, van Houten D, Damjanov N, Schneider C, Cengel K, Metz DC: Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study. Cardiovasc Intervent Radiol 2024.
2c
7
1d
1f
Selected Publications
1ec Janjigian YY, Al-Batran S-E, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh D-Y, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Fivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland J, Tabernero J, MATTERHORN Investigators: Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med 2025.1e3 Capdevila J, Artamonova E, De Jesus Acosta A, Niccoli P, Toth M, Ramirez R, Hendifar A, Cingarlini S, Trikalinos NA, Quante M, Garcia-Carbonero R, Goder E, del Rivero J, Eads JR, Odeleye-Ajakaye A, Gozman A, Naik GS, Spada F: Belzutifan for advanced pancreatic neuroendocrine tumors (panNETs): results from cohort A2 of the phase 2 LITESPARK-015 study. European Society of Medical Oncology Annual Meeting 2025.
159 Eads JR, Morelli MP, Olson D, Litten JB, Astrow SH, Pelster M: A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers. J Clin Oncol 2025.
23e Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O’Hara MH, Eads JR, King D, Shah MM, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA: Incorporating circulating tumor DNA testing into clinical trials: a position paper by the National Cancer Institute GI Oncology circulating tumor DNA working group. JCO Precision Oncology 2025.
21e Eads JR, Graham N, Gibson MK, Rajdev L, Chakravarthy AB, Khullar OV, Lin SH, Wistuba II, Agarwal R, Blazar M, Mehta DR, Al Baghdadi T, Jin N, Massa RC, Hamilton SR, Staley CA, Wong TZ, O’Dwyer PJ: A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients with locoregional esophageal and gastroesophageal junction adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). J Clin Oncol 2024.
132 Lee H, Kipnis S, O’Brien S, Eads JR, Katona BW, Pryma DA: Real-world 177Lu-DOTATATE peptide receptor radionucleotide therapy: treatment outcomes with dosing variations an in non-midgut neuroendocrine tumors. ASCO GI Symposium 2024.
d3 Eads JR: Episode 26: Neuroendocrine Neoplasms: Focus on Immunotherapy. Los Angeles Carcinoid Neuroendocrine Tumor Foundation Podcast 2024.
1c2 Li Y, Wu S, Zhao Y, Dinh T, Jiang D, Selfridge JE, Myers G, Wang Y, Zhao X, Tomchuck S, Dubyak G, Lee RT, Estfan B, Shapiro M, Kamath S, Mohamed A, Huang SC, Huang AY, Conlon R, Krishnamurthi S, Eads J, Willis JE, Khorana AA, Bajor D, Wang Z: Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer. J Clin Invest 2024.
c7 Chapin WJ, Massa R, Eads JR: Defining the role of neoadjuvant therapy for gastroesophageal cancers. Advances in Oncology 2024.
17e Soulen MC, Teitelbaum UR, Mick R, Eads J, Mondschein JL, Dagli M, van Houten D, Damjanov N, Schneider C, Cengel K, Metz DC: Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study. Cardiovasc Intervent Radiol 2024.
2c